The World Health Summit brings together leading researchers, physicians, government officials, and representatives from industry and civil society worldwide.
Find a comprehensive list here
Born in London, Dr. Cary Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a master’s degree (with distinction) in Business Administration. He is a Harvard Business School Alumni having attended the school’s Executive General Management programme in 2003. In 2009, Dr. Adams made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva. UICC unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda. Its rapidly increasing membership base of over 1100 organisations in more than 170 countries features the world’s major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners. Dr. Adams and his team focus on global advocacy, convening the cancer community (through World Cancer Day, the World Cancer Congress and the World Cancer Leaders’ Summit) and running significant global capacity building projects that address global cancer issues. Dr. Adams also serves as a member of the Board of Directors of the NCD Alliance, a coalition of around 2,000 organisations working on non-communicable diseases, which include cancer, diabetes, heart, respiratory, mental and neurological diseases. He is also an advisor to the City Cancer Challenge Foundation and the McCabe Centre for Law on Cancer. In 2014, he was awarded an Honorary Doctorate in International Relations from the University for Business and International Studies in Geneva and in 2015, an Honorary Doctorate in Health from Bath University in the UK. In May 2015, Dr. Adams was awarded ‘CEO of the year’ at the International and European Association conference organised by the Associations Network.
Dr. Tedros Adhanom Ghebreyesus has been Director-General of the World Health Organization since 2017. Upon assuming office, he outlined five key priorities for the WHO: universal health coverage; health emergencies; women’s, children’s and adolescents’ health; health impacts of climate and environmental change; and a transformed WHO. Tedros is globally recognized as a health scholar, researcher, and diplomat with first-hand experience in research, operations, and leadership in emergency responses to epidemics. He previously served as Ethiopia’s Minister of Foreign Affairs, Ethiopia’s Minister of Health, and Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria.
Ann Aerts has been Head of the Novartis Foundation since January 2013. During this time, she has been leading an organization committed to catalyzing innovations that transform the health of low-income populations. Since 2019, the Novartis Foundation sharpened its focus to concentrate on how digital technology, data science and artificial intelligence can reimagine health and care around the world. Ann holds a Degree in Medicine and a Masters in Public Health from the University of Leuven, Belgium, as well as a Degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp, Belgium. She also holds a Certificate in Applied Epidemiology from the CDC in Atlanta, US, and a Certificate of Executive Development from the IMD Business School, Lausanne, Switzerland.
Dr Svetlana Akselrod is Director of the World Health Organization (WHO) Global Noncommunicable Diseases (NCD) Platform, and leads a coordinated multisectoral and multi-stakeholder action in the fight against major killers of our time – NCDs. The Global NCD Platform brings together the UN Inter-Agency Task Force on NCDs and the Global Coordination Mechanism on NCDs, and oversees a number of other cross-cutting initiatives on NCDs at global, regional and country levels. Prior to that, Dr Akselrod held the position of WHO’s Assistant Director-General for NCDs and Mental Health, leading WHO’s work in tackling NCDs and their major risk factors. She led the preparatory process for the Third United Nations General Assembly High-level Meeting on NCDs, coordinated the work of the WHO Independent High-level Commission on NCDs and co-chaired the WHO Civil Society Working Group on NCDs. Before joining WHO, Dr Akselrod served for more than 11 years in high-level roles at the Ministry of Health of the Russian Federation, holding the position of Deputy Director at the Department of International Cooperation and Public Affairs. Among Dr Akselrod’s key professional achievements were the inclusion of NCDs, HIV/AIDS, tuberculosis, maternal and child health, antimicrobial resistance and malaria as key priorities in the national and international agendas of the Russian Federation.
Professor Pascale Allotey is the Director of the United Nations University International Institute for Global Health (UNU-IIGH). She has two decades of experience as a researcher in global health including multidisciplinary background, and experience working across four continents to promote health and well-being.
Bill Anderson is the CEO of Roche Pharmaceuticals. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Bill serves as a member of Roche's Executive Committee, overseeing the Pharmaceutical division. Leading an organisation of 55,000 people, he is passionate about helping people make meaningful progress every day on the things that matter to patients. With a world-leading investment in R&D, his vision is to bring more medical advances to patients at less cost to society. His tenure at Roche has seen him serve as the CEO of Genentech, the Head of Global Product Strategy and in roles leading the US Oncology and Immunology business units. Bill has a bachelor's degree in chemical engineering from the University of Texas and earned masters degrees in management and chemical engineering from the Massachusetts Institute of Technology.
Inger Ashing is Chief Executive Officer (CEO) of Save the Children International. A respected child rights activist, Inger has been associated with Save the Children for more than 25 years, first serving as a youth advocate and later on the Boards of Save the Children Sweden and Save the Children International. Prior to her appointment in September 2019, Inger was Director General at the Swedish Agency against Segregation, a Swedish government agency, where she worked to reduce segregation and social inequality, with a special focus on improving the situation in socio-economically disadvantaged areas. She has also served as the National Coordinator for Youth Not in Education or Employment for the Swedish Government, Deputy Director General of the Swedish Agency for Youth and Civil Society and the CEO of the Global Child Forum. Inger is also a member of the Ethics Council at The Swedish Migration Agency. She has been an expert to and board member of several authorities and committees such as the Delegation for Human Rights, the Swedish National Knowledge Centre on Violence against Children, the Delegation for the Employment of Young People and Newly Arrived Migrants, the Swedish Enforcement Authority, the National Board of Institutional Care, and the Monitoring Committee for The European Social Fund.
Ricardo Baptista Leite is a doctor trained in infectious diseases and Head of Public Health at Católica University of Portugal. He is a member of the Portuguese National Parliament, the Vice-President of the Social Democratic Party Parliamentary Board and National Spokesperson for Health of the Social Democratic Party in Portugal. Baptista Leite is the Founder and President of ‘UNITE – Global Parliamentarians Network to End Infectious Diseases, a global platform of current and former policy makers created under the auspices of UNAIDS and committed to ending public health threats such as HIV/AIDS, viral hepatitis and other infectious diseases by 2030 in accordance with the UN SDGs. He is also the Vice President of the ‘Parliamentary Network on The World Bank & International Monetary Fund’ and Global Ambassador of the ‘G20 Health & Development Partnership’.
Since January 2021, José Manuel Barroso is Gavi’s Board Chair. He served as Prime Minister of Portugal from 2002-2004 and as President of the European Commission from 2004-2014, accepting the Nobel Peace Prize on behalf of the European Union in 2012. He is currently non-executive Chairman of London-based Goldman Sachs International. Barroso was elected several times to the Portuguese Parliament (Assembleia da República) and served as Chairman of its Committee on Foreign Affairs and Cooperation. He was successively State Secretary in the Ministry of Internal Administration, State Secretary for Foreign Affairs and Development Cooperation and Minister for Foreign Affairs. Barroso is also a Visiting Professor at Universidade Católica Portuguesa and Director of the Center for European Studies at its Institute for Political Studies. He is a Visiting Professor at the Graduate Institute of International and Development Studies in Geneva and teaches at the School of Transnational Governance of the European University Institute in Florence. He is a Non-Resident Senior Fellow with the Liechtenstein Institute on Self-Determination at Princeton University. He has published several books and articles in academic journals on political science and international relations. Barroso graduated in Law, and has a Master in Law from the University of Lisbon, as well as a Master in Economic and Social Sciences/Political Science from the University of Geneva. He also holds a post-graduate diploma from the University Institute of European Studies in Geneva. Barroso has received numerous honorary distinctions from countries around the world. Among these, there are 35 decorations, including from Portugal, Brazil, Spain, Germany, France and the United Kingdom.
Dr. Christoph Benn is the Director for Global Health Diplomacy at the Joep Lange Institute in Amsterdam and Senior Advisor at the Global Fund to fight AIDS, tuberculosis and malaria in Geneva. He has been a member of the founding board at the creation of the Global Fund in 2002. As Director of External Relations from 2003–2018 he has been responsible for mobilizing the financial resources for the Global Fund through the management of its regular replenishment cycles and spearheading innovative approaches to resource mobilization including (Product) RED and Debt2Health. Under his leadership the Global Fund has mobilized pledges and contributions of more than USD 50 billion. At the Joep Lange Institute Christoph is focusing on accelerating UHC in LMICs through innovations in digital health and in international health financing. He has extensive experience in managing political relations with governments, multilateral organizations, Civil Society and the Private Sector. Christoph is a physician with an MD from the University of Giessen (Germany), a Diploma in Tropical Medicine&Hygiene from the Liverpool School of Tropical Medicine, and an MPH from the Johns Hopkins School of Public Health.
Dr. Seth Berkley is the CEO of Gavi, the Vaccine Alliance since 2011. He founded the International AIDS Vaccine Initiative (IAVI) in 1996, where he served as President and CEO. Prior to that, he worked for the Health Sciences Division at The Rockefeller Foundation, held posts at the Center for Infectious Diseases, the US Centers for Disease Control; the Massachusetts Department of Public Health; and the Carter Center, where he was assigned as an epidemiologist to the Ministry of Health in Uganda.
Dr Catharina Boehme has been Chief Executive Officer of FIND (Foundation for Innovative New Diagnostics) since 2013, previously holding positions as Chief Medical Officer and head of the organization’s tuberculosis (TB) programme. She is a member of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), as well as sitting on several other WHO/UN boards. She also served as Lancet Commissioner for TB, Diagnosis and Precision Global Health, and Co-chair of the New Diagnostics Working Group of the Stop TB Partnership. Prior to joining FIND, Catharina worked as programme coordinator for the Department of Infectious and Tropical Diseases in Munich, Germany, and established a TB research unit at Mbeya Medical Research Program in Tanzania. She holds a Doctor of Medicine degree in Internal Medicine (Ludwig Maximilians University Munich, Germany) and diplomas in Public Health (Charite) and in Management & Leadership (IMD).
Borrero studied Neurosurgery at the Mexican Institute of Social Security and has a sub-specialization in Spinal Surgery at the Ochsner Clinic-Health System in New Orleans, EEUU. In addition, he has a Diploma in Health Administration from Harvard University in Boston. Also, he was resident physician at the Vozandes Hospital in Quito, and head of the Neurosurgery department at the Metropolitan Hospital in Quito and at Ecuador’s Society for the Fight Against Cancer (SOLCA). As part of his experience, he founded the Health Sciences Faculty in the University of the Americas (UDLA), of which he was dean, and created the Master in Management of Health Institutions for the UDLA Business School. He participated in the board of directors of “Salvar Vidas” initiative, which managed the donation of USD 12 million in equipment, medicines and supplies for hospitals during the COVID-19 pandemic. On May 24, 2021, Alfredo Borrero Vega was installed by the National Assembly as Constitutional Vice president of the Republic of Ecuador. His work is focused on transforming Ecuador’s health system, employment generation, entrepreneurship support and the country’s post-pandemic productive reactivation.
Rick Bright is currently the Senior Vice President, Pandemic Prevention and Response at The Rockefeller Foundation leading the development of the Foundation’s pandemic data and action platform that will prevent future pandemics by identifying and triggering responses to the earliest alerts of a disease outbreak and stopping it in the first 100 days. Prior to this role, he served as the Deputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority (BARDA), in the U.S. Department of Health and Human Services. Prior to BARDA, Dr. Bright gained extensive experience in the biotechnology industry where he served in senior leadership and executive management roles. Dr. Bright has held senior scientific leadership positions in non-governmental organizations where he championed innovative vaccine development and manufacturing capacity expansion in developing countries. He also spent a decade in vaccine and therapeutics development at the Centers for Disease Control and Prevention. For this work, Dr. Bright received the Charles C. Shepard Science Award for Scientific Excellence. Dr. Bright serves as an international subject matter expert in biodefense, emergency preparedness and response, vaccine, drug and diagnostics development and served as an advisor to the Biden Administration, World Health Organization, development of the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. Dr. Bright received a Ph.D. in Immunology and Molecular Pathogenesis from Emory University and a B.S. magna cum laude in Biology and Physical Sciences from Auburn University at Montgomery.
Winnie Byanyima is the Executive Director of UNAIDS and Under-Secretary-General of the United Nations. A passionate and longstanding champion of social justice and gender equality, Ms. Byanyima leads the United Nations efforts to end the AIDS epidemic by 2030. Ms. Byanyima believes that health care is a human right and has been an early champion of a People’s Vaccine against the coronavirus that is available and free of charge to everyone, everywhere. Before joining UNAIDS, Ms. Byanyima served as the Executive Director of Oxfam International. Ms. Byanyima was elected for three terms and served eleven years in the Parliament of her country, Uganda. She led Uganda's first parliamentary women’s caucus, championing ground-breaking gender equality provisions in the county's 1995 post-conflict constitution. Ms. Byanyima led the establishment of the African Union Commission’s Directorate of Gender and Development and also served as Director of Gender and Development at UNDP. She founded the Forum for Women in Democracy (FOWODE), an influential Ugandan NGO, and has been deeply involved in building global and African coalitions on social justice issues. A global leader on inequality, Ms. Byanyima has co-chaired the World Economic Forum and served on the World Bank’s Advisory Council on Gender and Development, ILO’s Global Commission on the Future of Work and the Global Commission on Adaptation.
Dr. Carrie L. Byington is the Executive Vice President (EVP) for the University of California’s health enterprise and a Professor of Pediatrics at the University of California, San Francisco. In her role as EVP, Dr. Byington leads the country’s largest public academic health care system. UC’s health delivery and education enterprise is comprised of six academic health centers which include 12 hospitals and 20 health science schools, many of which are ranked among the country’s best. In her role, she has led the COVID-19 response for the UC System including preparing hospitals for surge, protecting ~ 100,000 health care workers, developing testing, supporting the health and safety of ~ 600,000 students and employees on 10 campuses, coordinating the COVID vaccine roll-out, and partnering with the state of California to provide expertise and capacity for pandemic response. Trained as a pediatrician specializing in the treatment of infectious diseases, Dr. Byington is a member of the National Academy of Medicine. She is a patent holder and member of the National Academy of Inventors. She previously served as Chair of the American Academy of Pediatrics’ (AAP) Committee on Infectious Diseases (2014-2018) and is an expert on bacterial and viral respiratory pathogens, pathogens with pandemic potential, and vaccine-preventable infections. In her role with the AAP, she has been an external advisor and technical expert to the CDC on evaluation of children with suspected or confirmed Ebola, EVD68, influenza, and Zika viruses and other infectious diseases. Her research team contributed to the development of the FDA-cleared BioFire diagnostic platform which includes an EUA for the Respiratory Panel 2.1which tests for SARS-CoV2 and 21 other pathogens. She chairs the Association of Academic Health Centers President’s Council on Health Security.
Agnès Callamard is a French human rights expert who is the Secretary General of Amnesty International. She was previously the Special Rapporteur on extrajudicial, summary, or arbitrary executions appointed by the United Nations Human Rights Council. She is also the Director of Columbia University's project on Freedom of Expression-globally.
Helen Clark was elected Prime Minister of New Zealand first in 1999 and then twice more in 2002 and 2005. Clark joined the Labour Party in 1971 and during the following decade held a variety of positions within the party. In parliamentary elections in 1975, she was selected as the Labour candidate for a seat that was considered safe for the conservative National Party. Although she lost that election, she was elected to Parliament from a different constituency in 1981and won ten consecutive elections there. As Chair of the Foreign Affairs and Defence Select Committee and of the Disarmament and Arms Control Select Committee (1984–87), she played a major role in the country’s adoption of a nuclear-free stance which has been embraced across the political spectrum. From 1987 to 1990, Clark was a Cabinet Minister, holding at various times the portfolios of housing, conservation, labour, and health. In 1989–90, she also served as Deputy Prime Minister and in 1990 was appointed to the Privy Council, becoming the first woman in New Zealand to hold those offices. After the National Party returned to power in 1990, Helen Clark served as Deputy Leader of the Opposition from 1990-93, and then as Leader of the Opposition until the Labour Party was able to form a governing coalition following the 1999 elections. She was the first woman to lead a party to electoral victory in New Zealand. As Prime Minister, Clark also held the portfolio of arts and culture and appointed a diverse team of ministers which included 11 women and 4 Maori. During her nine years as Prime Minister, New Zealand enjoyed strong economic growth, low unemployment, and significant investment in public services. It set clear objectives for sustainable development and climate action. It also prioritised reconciliation and the settlement of historical grievances with New Zealand’s indigenous people and the development of an inclusive multicultural and multi-faith society.
Professor Awa Marie Coll Seck, Minister of State to the President of the Republic of Senegal MD, PhD, Specialist in Infectious diseases and Bacteriology-Virology, Prof. Awa Marie Coll Seck is currently serving as Minister of State to the President of the Republic of Senegal since 2017. She chairs the National Committee of the Extractive Industries Transparency Initiative (CN-ITIE). Prof. Coll Seck has been twice Minister of Health in Senegal (2001-2003 / 2012-2017). She was named “Best Minister in the World” in Dubai in February 2017 at the World Government Summit. She had the responsibility of directing the Department of Infectious Diseases at Cheikh Anta Diop University in Dakar, Senegal. Prof. Coll Seck was Executive Director of the Roll Back Malaria Partnership (RBM) from 2004 to 2012, and Director of the Department of Policy, Strategy and Research of UNAIDS (1996-2001). Professor Awa Marie Coll Seck is a member of the Board of Directors of Grand Challenges Canada, of Resolve to save lives, of the Jury of the ISA Prize of Bahrain, and of the Jury of the Noguchi Africa Prize (Japan). She is also a member of the Advisory Board of the Harvard Ministerial Leadership Program (USA) and a member of the High Level Advisory Board of Examples in Global Health. She is also appointed as Unaffiliated Board Member and member of the Programme and Policy Committee of Gavi, the Vaccine Alliance Prof. Awa Marie Coll Seck chairs the Scientific Committee of the Forum Galien Africa and is a member of the Honorary Committee of the Prix Galien Africa. Professor Awa Marie Coll Seck is the author of more than 150 scientific publications.
Francesca Colombo, M.Sc., is Head of the Health Division at the Organisation for Economic Cooperation. She is responsible for OECD work on health, which aims at providing internationally comparable data on health systems and applying economic analysis to health policies, advising policy makers, stakeholders and citizens on how to respond to demands for more and better health care and make health systems more people centred. Major activities under her responsibility cover the response to the COVID-19 crisis and solutions to make health systems more resilient; trends in health spending; measuring of health care outcomes, activities and inputs; health care quality policies; assessing health system efficiency and value for money; health workforce; long-term care systems and ageing; the economics of public health; pharmaceutical policies, new technologies, big data and Artificial Intelligence in health. Major publications resulting from the work of the Division she manages include Health at a Glance, Health in the 21st Century: Putting Data to Work for Stronger Health Systems, Realising the Full Potential of Primary Health Care, Attracting and Retaining Care Workers for the Elderly, Tackling Wasteful Spending on Health, The Heavy Burden of Obesity, Making Mental Health Count. Mrs Colombo has over 20 years of experience leading international activities on health and health systems. Over her career, she travelled extensively in Europe, South America and Asia, advising governments on health system policies and reforms.
Thomas B. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies, based in Geneva. He represents the innovative biopharmaceutical industry on the Access to COVID-19 Tools (ACT) Accelerator, a unique global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. Thomas Cueni has been instrumental in creating the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance. Prior to joining IFPMA he was Secretary General of Interpharma (Switzerland) and was a member of the Board and Chair of the European Federation of Pharmaceutical Industries and Associations. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”. He served as a Swiss diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).
Gabriela Cuevas Barron has been a member of the UHC Movement Political Advisory Panel of UHC2030 Steering Committee since 2020. Active in politics since she was 15 years old, she was elected Federal Member of Parliament for the first time at age 21. She has been Federal Member of Parliament three times, Local Member of Parliament, and a Constituent Member of Parliament in the Constituent Assembly of Mexico City. Additionally, she was the first woman to be elected Mayor of the Miguel Hidalgo Delegation. She also chaired the Foreign Relations Commission when she served as Senator. She is a Member of the High-Level Steering Group of Every Woman, Every Child, and Co-Chair of The Lancet COVID-19 Commission’s Task Force on Humanitarian Relief, Social Protection, & Vulnerable Groups. She is also a member of the Task Force on Global Health Diplomacy and Cooperation, and the Regional Task Force for Latin America. In 2017 Gabriela Cuevas Barron became the youngest and the second woman President of the Inter-Parliamentary Union (IPU). In her term, Gabriela worked to increase the prominence and prestige of the IPU as the global institution for parliamentarians. She is Honorary President of the IPU. She was decorated with the grade of Chevalier de la Légion d’Honneur by the Government of France, and the Cavaliere di Gran Croce, Ordine Equestre di Saint’ Agata on behalf of the Government of the Republic of San Marino.
Dame Sally is UK Special Envoy on Antimicrobial Resistance. Before this, she was Chief Medical Officer (CMO) for England and Chief Medical Adviser to the UK government from March 2011 to September 2019, having held the post on an interim basis since June 2010. Dame Sally advocates globally on AMR. She has spoken on AMR at numerous events including the World Health Assembly side events, the G8 science ministers’ meeting in 2015, the Global Health Security Initiative in 2015, and the UN General Assembly side event in 2016. She was chair of the 2013 AMR forum at the World Innovation Summit for Health (WISH) and was for three years the chair of the WHO Strategic and Technical Advisory Group on AMR. Most recently, Dame Sally has been appointed a co-convener of the UN Inter-Agency Co-ordination Group on AMR, set up in response to the AMR declaration made at UNGA 2016. Dame Sally was a member of the World Health Organization (WHO) Executive Board 2014-2016 and has led delegations to a range of WHO summits and forums since 2004.
Dr Nicole de Paula is the first Klaus Töpfer Sustainability Fellow awardee at the International Institute for Sustainable Development (ASS) in Potsdam, Germany. For more than a decade, she has been globally connecting policymakers and researchers to create a public understanding on key issues related to sustainability, environment and public health. Previously of her work in Germany, she was the director of a think-tank in Bangkok, Thailand, hosted by Mahidol University at the Faculty of Public Health. As a Planetary Health advocate, she champions the socioeconomic advancement of women through environmental conservation and public health policies to make the 2030 Agenda for Sustainable Development a reality by 2030. She is the founder of the Women Leaders for Planetary Health and co-founder of an interdisciplinary research group on Planetary Health at the University of Sao Paulo, Brazil. She is currently member of the global committee preparing the global meeting of the Planetary Health Alliance, to be held in Brazil in April 2021. Dr Nicole de Paula holds a Ph.D. in International Relations from Sciences Po Paris and has been consulting with several international organizations under the UN system on themes related to climate change, biodiversity, chemicals, financial and urban affairs. In the past, she has also been the French Embassy fellow at the Center for Transatlantic Relations at the Johns Hopkins University in Washington D.C. and a researcher at the London School of Economics and Political Science as part of the Global Public Policy Network (GPPN). Since 2012, Dr Nicole de Paula, is also a team leader and writer for the reputable Earth Negotiations Bulletin, published by the International Institute for Sustainable Development (IISD). Her most recent research focuses on decision making and international cooperation in the post-Covid19 world, as well as digitalization and sustainability. In 2020, Dr Nicole de Paula successfully concluded the executive course 'Blockchain: Technologies and Applications for Business' at Berkeley Haas School of Business, University of California. She is currently the review editor for the journal Frontiers in Public Health (Planetary Health) and for the Brazilian Journal of International Politics.
Dr. Roopa Dhatt is a physician by training and an advocate by principle, striving for greater health and well-being for all people through working in global health. She is the Executive Director and co-founder of Women in Global Health, a movement that strives to bring greater gender equality to global health leadership. Since its foundation Women in Global Health, an organization staffed entirely by volunteers, has expanded to become a global movement, with chapters in four continents and more than 21,000 followers in 90+ countries.
Alan was first elected to the European Parliament in 1989, representing the constituency of Tyne and Wear, re-elected to a second term in 1994 and finally elected to represent the North East of England in 1999. He was Leader of the Labour Party in Europe until his retirement from the EU Parliament in January 2000. Alan led the European Parliamentary Delegation to the special G7 summit on the development of the global information society, sharing the platform with the US Vice-President, Al Gore. In February 2000, Alan Donnelly became the Executive Chairman of his own company, Sovereign Strategy. Due to his extensive work in the sustainability, global health and development field, Alan has created a ‘G20 Global Health Partnership Initiative’, in consultation with international health stakeholders. The initiative included a lynchpin ‘G20 Global Health Innovation’ roundtable in Berlin on April 28th 2017 hosted by the co-sponsors. On the basis of the success to bring together key global health stakeholders from the public, academic and private space, Alan and the co-sponsor fundamentally contributed to bringing global health challenges on the Following an increasing interest to maintain and build the momentum of this initiative, Alan has created Sovereign Sustainability and Development (SSD) in late 2017 that act as the convener and secretariat of ‘The G20 Health and Development Partnership’. Alan has become the Executive Chairman of SSD and the Patron of the G20 Health and Development Partnership. Following consultation with a number of key stakeholders and confirmation from the Government of Argentina that health would remain a focus of the G20 under its Presidency (2018), a Working Session was scheduled in the UK Houses of Parliament in December 2017 in order to begin to collectively plot a course for the Partnership. For his work on German Unification, Alan was honored with the title, ‘Knight Commander of Germany’ from the German state in 1991.
Dr Ruxandra Draghia-Akli, is Global Head, Johnson & Johnson Global Public Health R&D. In this role, Ruxandra and her team advance Global Public Health into the next era of innovation by leveraging discovery, development and regulatory capabilities. She provides alignment with the overall end-to-end strategy of J&J Global Public Health, collaborating with the Infectious Disease & Vaccines Therapeutic Area and other R&D Therapeutic Areas that have assets with application in global public health settings. She also collaborates with the J&J Innovation Centers and external partners to build important networks and identify new opportunities. Ruxandra’ expertise includes impactful work within industry, government and academia. She led Public Health and Scientific Affairs for vaccines at Merck, and previously, she worked for the European Commission, first as Director and later as Deputy Director General, overseeing programmatic, legislative, and research & innovation policy issues, and contributing to the Commission’s Health strategy for improving public health. Her career started as medical doctor and researcher in Romania, France and US. She holds a MD degree, and a Ph.D. in human genetics from the Romanian Academy of Medical Sciences, undertook doctoral training at University Rene Descartes in Paris, France and a postdoctoral training at Baylor College of Medicine, Houston, Texas, with a focus on gene therapy and novel vaccines; Ruxandra has authored and co-authored more than 100 papers and holds over 100 patents.
Christian Drosten is the Director of the Institute of Virology of the Charité - Universitätsmedizin Berlin. He has become an internationally respected COVID-19 expert. In 2003 he discovered the unknown virus causing SARS and developed a diagnostic test that enabled public health authorities worldwide to stop a beginning pandemic. Drosten has co-authored more than 300 peer-reviewed papers and coordinated research consortia funded by the European Union, Deutsche Forschungsgemeinschaft, and the German Ministry of Research. He is a member of the internal advisory board of the German Center for Infection Research (DZIF) and the speaker of the German National Research Network for Zoonotic Infections. He received the German Federal Cross of Merit for his work to counter the SARS epidemic.
Dr Catherine Duggan is the CEO of the International Pharmaceutical Federation. She took up the role in June 2018. Catherine is responsible for visionary leadership, support, development and advocacy across the 144 member organizations and the four million members FIP represents. She is responsible for developing and delivery of the strategy, planning and working across global organizations such as WHO and UN, and other international professional groups. Catherine will chair the World Professions Health Alliance which represents 31 million health professionals across medicine, nursing, dentistry, physiotherapy and pharmacy. Upon taking up the role, Catherine was awarded an honorary Professorship from the School of Pharmacy, University of Nottingham. She has been awarded Fellowships of both the RPS and the UCL School of Pharmacy and is a Fellow of the Royal Society of Arts. Until April 2018, Dr Duggan was the Director of Professional Development at the Royal Pharmaceutical Society of Great Britain, where she was responsible for the delivery of professional advice and support to all members across all sectors; the development of strategies to share and showcase good practice across the profession and development and implementation of professional standards for pharmacy. From 2012, Catherine led the development, implementation and strategic embedding of RPS Faculty and Foundation programs into continuing professional development. Dr Duggan has published widely and presented at national and international meetings and has a wealth of people and program management experience. She is a recognized leader across the profession working with many networks within and across the profession and, more widely, health and business. Catherine has worked in community, primary care, hospital and academia. Between 2007 and 2009, Catherine was the Chair of the United Kingdom Clinical Pharmacy Association and then an elected member of the Council of the RPSGB.
Victor J. Dzau, M.D., is the President of the US National Academy of Medicine (NAM), and Vice Chair of the US National Research Council. Professor Dzau is Chancellor Emeritus of the Duke University. Previously, he was Chairman of Medicine at Harvard, as well as Stanford Universities. Professor Dzau is highly regarded as a trailblazer in translational research, health innovation, and global health. His seminal work laid the foundation for development of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Professor Dzau pioneered gene therapy for vascular disease. As one of the world’s preeminent health leaders, he has served as Chair of the NIH Cardiovascular Disease Advisory Committee and now chairs the NIH Cardiovascular Stem Cell Consortium. He is a member of Health Biomedical Sciences Advisory Council of Singapore. He was on the Board of Health Governors of the World Economic Forum and currently chairs its Council on Healthy Longevity. Professor Dzau is active in global health. He has served as interim board member of CEPI, engaged with the global response to COVD-19 as a member of the Global Preparedness Monitoring Board, a principal of the ACT-Accelerator which includes COVAX, a principal of the ACT-Accelerator which includes COVAX, Advisor to the G20 High Level Independent Panel on Financing and co-chair of the G20 Scientific Expert Panel on Global Health Security. Leading the National Academy of Medicine, Professor Dzau has launched important initiatives such as the Global Health Risk Framework (2016), Crossing the Global Quality Chasm (2018), Human Genome Editing (2017) and the NAM Grand Challenge in Human Health and Climate Change.
Jeremy Farrar is Director of the Wellcome Trust, a global charitable foundation (both politically and financially independent) which exists to improve health for everyone by helping great ideas to thrive. Jeremy is a clinician scientist who before joining Wellcome was, for eighteen years, Director of the Clinical Research Unit in Viet Nam, where his research interests were in infectious diseases, tropical health and emerging infections. He has contributed to almost 600 peer-reviewed scientific papers and served on several global advisory committees. In 2015 he was recognised by Fortune magazine as 12th in the top 50 of the World’s Greatest Leaders.
Dr. Maria Flachsbarth joined the Christian Democratic Union of Germany (CDU) in 1991. She became a member of the German Parliament in 2002. Since 2006, she has been deputy chair of the CDU in the state of Lower Saxony, and since 2007, she has chaired the CDU district association for Hanover. From 2002 to 2013, she served on the Parliamentary Committee on the Environment, Nature Conservation and Nuclear Safety. From 2009 to 2013, she chaired a Parliamentary Committee of Inquiry on the envisaged radioactive waste disposal facility at Gorleben, and she was the special representative for churches and religious communities of the CDU/CSU parliamentary group. Then from the end of 2013 to March 2018, she served as Parliamentary State Secretary to the Federal Minister of Food and Agriculture. Since March 2018, she has been Parliamentary State Secretary to the Federal Minister for Economic Cooperation and Development.
Henrietta H. Fore has been UNICEF’s Executive Director since 2018. She has worked to champion economic development, education, health, humanitarian assistance and disaster relief in a public service, private sector and non-profit leadership career that spans more than four decades. She has previously served as Administrator for USAID and Director of United States Foreign Assistance, Undersecretary of State for Management at the US Department of State, Director of the United States Mint in the US Department of Treasury, and Chair of the Board and Chief Executive Officer of Holsman International, a manufacturing and investment company.
Jayati Ghosh is an Indian development economist. She is the Chairperson of the Centre for Economic Studies and Planning at the Jawaharlal Nehru University, New Delhi and her core areas of study include international economics, employment patterns in developing countries, macroeconomic policy, and issues related to gender and development. She is also Professor of Economics at the University of Massachusetts Amherst. Ghosh attended Delhi University for her undergraduate and got her M.A., M. Phil. in economics from Jawaharlal Nehru University. She joined Cambridge University for her PhD after winning the Inlaks Scholarship. Ghosh has previously held positions at Tufts University and Cambridge University, lecturing meanwhile at academic institutions throughout India. She is one of the founders of the Economic Research Foundation, New Delhi, a non-profit trust devoted to progressive economic research. She is also the Executive Secretary of the International Development Economics Associates (IDEAS). Ghosh was the principal author of the West Bengal Human Development Report which has received the United Nations Development Programme Prize for excellence in analysis. In addition to her many scholarly articles, she writes regular columns on economics and current affairs. n Spring Term 2011, Ghosh served as the first Ragnar Nurkse Visiting Professor in Development Economics at Tallinn University of Technology's Technology Governance graduate program. In 2021, she was appointed to the World Health Organization's Council on the Economics of Health For All, chaired by Mariana Mazzucato.
Dr. Gitahi is the Group CEO/Director-General Amref Health Africa and also Co-Chair of the UHC2030 WHO and World Bank initiative for achievement of UHC by 2030. Until his appointment at Amref Health Africa, Dr Gitahi was the Vice President and Regional Director Smile Train, a Global cleft charity. As a medical doctor, he worked both in the public and private sector. He has extensive experience working in the private sector having worked in senior executive roles at GlaxoSmithKIine and Nation Media Group.
He is also member of the Private Sector Advisory Board of Africa CDC and of the World Health Organization’s Community Health Worker Hub. He is member of the Board of Directors of The Standard Group and holds board member positions across Amref Health Africa offices in Africa.
Roland Göhde is Chairman of the Board at GHA - German Health Alliance, an initiative of BDI - Federation of German Industries, jointly established with the German government in the year 2010, and he is Senior Managing Director of the German diagnostics and biotechnology company Sysmex Partec. Before, he had the position as HIV/AIDS Project Coordinator at Partec, subsequently as Director of the Partec Essential Healthcare Division and from 2000 to 2014 as Managing Partner. Göhde is a Member of the UNAIDS Health Innovation Exchange Advisory Board, the World Health Summit Council, the Management Board of the German-African Business Association 'Afrika-Verein', the Board of the BDI Committee on the healthcare industry, and Chair of the Private Sector Advisory Board of GIZ. In addition, he is the main initiator of the 'Action Group on Ebola' and the 'German-African Healthcare Symposium' launched in 2014. Göhde has been active as Chairman of the Board of the Free State of Saxony biotechnology/life sciences association 'biosaxony' from 2009 to 2016. From 2012 to 2014 he acted as Founding Member of the Advisory Board of the Coordinating Agency for the Free State of Saxony Healthcare Sector. Roland Göhde is Co-Founder and Member of the Board of the charitable Göhde Foundation, established in 2012.
Charles Gore is the Executive Director of the Medicines Patent Pool. He took up the post in July 2018 following a career in patient representation and public health advocacy. He has advanced the work of the MPP in HIV and Hepatitis and is opening up further opportunities for the MPP model of voluntary licensing to be used for patented medicines on the World Health Organization (WHO) essential medicines list. Following his own diagnosis with hepatitis C in 1995 and cirrhosis in 1998, Charles set up The Hepatitis C Trust (2002) and the European Liver Patients Assocation (2004). In 2007, Charles organized an international meeting of hepatitis patient organisations to agree on co-ordinated global action, which led to the annual World Hepatitis Day and a new NGO, The World Hepatitis Alliance, of which Charles was the first president. As a result of the Alliance's advocacy, the WHO adopted successive viral hepatitis resolutions, making World Hepatitis Day an official day (28 July) and endorsing the first Global Health Sector Strategy on viral hepatitis to eliminate hepatitis B and C by 2030. Charles also sits on a number of national and international advisory bodies, including the WHO Director-General’s Strategic and Technical Advisory Committee for Viral Hepatitis and has been a member of all WHO guideline development groups on testing and treating viral hepatitis.
António Guterres, the ninth Secretary-General of the United Nations, took office on 1st January 2017. Prior to his appointment as Secretary-General, Mr. Guterres served as United Nations High Commissioner for Refugees from June 2005 to December 2015, heading one of the world’s foremost humanitarian organizations during some of the most serious displacement crises in decades. Before joining UNHCR, Mr. Guterres spent more than 20 years in government and public service. He served as prime minister of Portugal from 1995 to 2002, during which time he was heavily involved in the international effort to resolve the crisis in East Timor. As president of the European Council in early 2000, he led the adoption of the Lisbon Agenda for growth and jobs, and co-chaired the first European Union-Africa summit. He was a member of the Portuguese Council of State from 1991 to 2002.
Sir Andrew Haines is Professor of Environmental Change and Public Health at LSHTM, with a joint appointment in the Department of Public Health, Environments, and Society and in the Department of Population Health. He was previously Director (originally Dean) of LSHTM for nearly 10 years, and before that Professor of Primary Health Care at University College London. He worked part-time as a general practitioner in North London for many years and has been a member of a number of major international and national committees. Haines was knighted in 2005 for his services to medicine.
Jane Halton is a former Secretary of the Australian Department of Finance, responsible for supporting the delivery of the Australian Government Budget, the ongoing management of the Australian Government’s non-defence domestic property portfolio, key assets and asset sales, plus the financial and performance framework for Australian Government agencies. She has extensive experience in finance, insurance, risk management, information technology, human resources, health and aging, sport, and public policy, as well as significant international experience. In a 33-year career within the public service, including nearly 15 years as Secretary, Ms. Halton’s previous roles include Secretary of the Australian Department of Health, Secretary for the Department of Health and Ageing, and Executive Co-ordinator (Deputy Secretary) of the Department of the Prime Minister and Cabinet. Ms. Halton is a member of the Boards of the Australia and New Zealand Banking Group (ANZ Bank), Clayton Utz, and the Australian Strategic Policy Institute. She is also a member of the Board for the Coalition for Epidemic Preparedness Innovations. Previously, Ms. Halton has held numerous international appointments including the Executive Board of the World Health Organization (2004–2007), President of the World Health Assembly (2007), Chair of the Executive Board of WHO, and Chair of the OECD Health Committee (2007–2012). Ms. Halton holds the positions of Adjunct Professor at the University of Sydney, and Adjunct Professor at the University of Canberra. She also holds a Doctorate of Letters Honoris Causa from the University of New South Wales. She was awarded the Public Service Medal in 2002, the Centenary Medal in 2003, and the Geneva Health Prize in 2013. In 2016, Ms. Halton became one of a small number of international members elected to the National Academy of Medicine in the United States.
Dr. Eckart von Hirschhausen (born 1967) studied medicine and science journalism in Berlin, London and Heidelberg. His specialty: conveying medical content in a humorous way and combining it with sustainable messages. For more than twenty-five years, he has been on the road as a moderator, speaker and motivator on stages, podiums and on television, and his books have sold more than five million copies. As an ambassador and advisory board member, he is active for, among others, Deutsche Krebshilfe, DFL Stiftung, Phineo and Fit-for-Future-Foundation. With his first foundation, HUMOR HILFT HEILEN, he promotes the humane in human medicine. Eckart von Hirschhausen is an honorary faculty member of Charité - Universitätsmedizin Berlin. He is a co-founder of Scientists for Future and supporter of the German Alliance Climate Change and Health (KLUG). In 2020, he established his second foundation Gesunde Erde - Gesunde Menschen (Healthy Planet - Healthy People) to research the scientific basis and the close connection between climate protection and health protection, to raise public awareness of this, to shape interdisciplinary collaborations to improve climate and health protection, and to actively contribute to solving the problems.
Richard Horton is Editor-in-Chief of The Lancet. He qualified in physiology and medicine with honours from the University of Birmingham in 1986. He joined The Lancet in 1990, moving to New York as North American Editor in 1993. Richard was the first President of the World Association of Medical Editors and he is a Past-President of the US Council of Science Editors. He is an honorary professor at the London School of Hygiene & Tropical Medicine, University College London, and the University of Oslo. He has received honorary doctorates in medicine from the University of Birmingham, UK, and the Universities of Gothenburg and Umea in Sweden. He now works to develop the idea of planetary health – the health of human civilizations and the ecosystems on which they depend.
David Humphreys is the global practice leader, health policy for Economist Impact, the division of The Economist Group developing in depth research and analysis of the biggest issues shaping our world. He leads a multidisciplinary team that conducts high quality clinical and policy analyses to inform micro level health decision making and produce macro level perspectives. Supporting clients across the health ecosystem for internal and external strategy making, David develops and directs engagements on such issues as evidence-based reviews of new health technologies, future healthcare challenges, value-based healthcare approaches for specific therapeutic areas, and impact of new policy initiatives.
An Infectious Disease Epidemiologist and consultant in Public Health Medicine, he has held public health and leadership positions in several national public health institutes for more than 20 years, including the Nigeria Centre for Disease Control, the South African National Institute for Communicable Diseases, the United Kingdom’s Health Protection Agency, and Germany’s Robert Koch Institute. He will start serving as Assistant Director-General at WHO leading the WHO Hub for Pandemic and Epidemic Intelligence in Berlin in November. His scientific research has been focused largely on intervention epidemiology.
Ambassador Ischinger is Chairman of the Munich Security Conference (MSC) and Senior Professor for Security Policy and Diplomatic Practice at the Hertie School of Governance in Berlin. He has served as German Deputy Foreign Minister (State Secretary) and as Germany's Ambassador in Washington, D.C. and London. In 2015, he chaired an OSCE-mandated ‘Panel of Eminent Persons on European Security as a Common Project’. From 2008 to 2014, he was also Global Head of Government Relations at Allianz SE, Munich. He is a member of a number of non-profit and corporate boards.
Adeeba Kamarulzaman became the first Asian President of IAS – the International AIDS Society, on 11 July 2020 when she began her two year term. Adeeba Kamarulzaman is currently Dean of the Faculty of Medicine at the University of Malaya, an Adjunct Associate Professor at Yale University, USA. She established the Infectious Diseases Unit at the University of Malaya Medical Centre and, in 2008, the Centre of Excellence for Research in AIDS (CERiA) at the same university. As convener of the Malaysian Harm Reduction Working Group of the Malaysian AIDS Council, she successfully advocated for the implementation of harm reduction measures to tackle HIV amongst people who inject drugs in Malaysia. She was President of the Malaysian AIDS Council from 2006 to 2010 where she remains an Executive Committee member. Adeeba Kamarulzaman also serves as Chairwoman of the Malaysian AIDS Foundation. Tatler Malaysia lists Adeeba among the most noteworthy Malaysian personalities.
Dr. Natalia Kanem is the Executive Director of the United Nations Population Fund (UNFPA), the United Nations sexual and reproductive health and rights agency. Appointed by United Nations Secretary-General António Guterres in 2017, Dr. Kanem has more than 30 years of strategic leadership experience in the fields of preventive medicine, public and reproductive health, social justice and philanthropy. Dr. Kanem holds a medical degree from Columbia University in New York, and a Master’s degree in Public Health with specializations in epidemiology and preventive medicine from the University of Washington in Seattle. She is a magna cum laude graduate of Harvard University in history and science.
After holding several positions including Staff Scientist at the Max Planck Institute for Immunobiology in Freiburg and Chair of the Department of Immunology at the University of Ulm, he became the Founding Director of the Max Planck Institute for Infection Biology in Berlin. Since 2019 he is Director Emeritus at this institute. The Microbiology and Immunology expert is a member of the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW) and the German National Academy of Sciences Leopoldina.
Annette Kennedy is the 28th President of the International Council of Nurses (ICN). She previously served as Third Vice President of the International Council of Nurses (ICN) from 2013-2017 and President of the European Federation of Nurses (EFN) from 2005-2007. Ms Kennedy, an Irish nurse, who was Director of Professional Development at the Irish Nurses and Midwives Organisation from 1994-2012, has extensive experience in dealing with policy issues at high levels and has long been involved with ICN through her vice-presidency and through her work as the President of the European Federation of Nurses (EFN) and as director of professional development for 19 years in the Irish Nurses and Midwives Organisation (INMO).
Professor Ilona Kickbusch is the founder of the Global Health Centre at the Graduate Institute, Geneva. She advises countries and organizations on their global health strategies and trains health specialists and diplomats in global health diplomacy and has had a distinguished career with the World Health Organization. She was key instigator of the Ottawa Charter for Health Promotion and WHOs Healthy Cities Network and continues to advise the WHO. As director of the Global Health Division at Yale University School of Public Health, Prof. Kickbusch was responsible for the first major Fulbright Program on global health.
Ilona Kickbusch is a member of the Global Preparedness Monitoring Board, acts as Council Chair to the World Health Summit, and is vice-president of the European Health Forum Gastein. She has been involved in German G7 and G20 activities relating to global health and the global health initiatives of the German EU presidency in 2020. She additionally chaired the international advisory board for the development of the German global health strategy. She has been awarded the Cross of the Order of Merit of the Federal Republic of Germany (Bundesverdienstkreuz) in recognition of her "invaluable contributions to innovation in governance for global health and global health diplomacy".
Professor Kickbusch’s key interests relate to the political determinants of health, health in all policies and global health. She also advocates for women leaders in global health.
Dr. Bronwyn King is a specialist radiation oncologist and founder and CEO of Tobacco Free Portfolios. She is also a Tobacco Control Ambassador for Cancer Council Australia and Diplomat of the Global Charter for World Federation of Public Health Federations. Dr. King has delivered two TEDx talks in the past year, calling for change in the global finance sector. A former elite swimmer, she was previously Team Doctor for the Australian Swimming Team.
Frederik Kristensen, MD has been the Deputy CEO of CEPI since January 2017. Before joining CEPI he was a senior advisor on innovation at the World Health Organization in Geneva, in the Family, Women’s and Children’s Health Cluster. Dr. Kristensen is a healthcare executive with previous experience from the Norwegian Development Agency, hospital management and the pharmaceutical industry. He has started and run successful companies in the areas of health economics and decision support. At the start of his career he worked as a general practitioner in rural settings. He is an MD from the Universities of Oslo, Norway and Newcastle-upon-Tyne, UK, with a MPH/MBA degree from the University of California, Berkeley.
Prof. Heyo Kroemer assumed his role as CEO of Charité Universitätsmedizin Berlin in September, 2019. He was previously Chairman of the Managing Board of the Göttingen University Medical Center and Dean of the Faculty of Medicine at Georg-August-Universität Göttingen. Prof. Kroemer’s medical background is in pharmacology, with a research focus on drug metabolism and transport. He represents the shareholder Charité – Universitätsmedizin Berlin in the WHS Foundation GmbH.
On 1 December 2019, Ms Kyriakides became the European Commissioner for Health and Food Safety. In the area of health, she is leading the Commission’s work on Europe’s Beating Cancer Plan, to help improve cancer prevention and care and is in charge of developing a new Pharmaceutical Strategy to ensure that Europe has enough affordable medicines to meet its needs. Her responsibilities also include supporting Member States in improving the quality and sustainability of health systems, creating a European Health Data Space to promote health-data exchange and support research. She is also in charge of ensuring full implementation of the European One Health Action Plan against Antimicrobial Resistance and working towards a global agreement on antimicrobials. Her responsibilities also include ensuring enforcement of animal welfare laws and promoting European standards globally as well as ensuring enforcement of EU laws on food safety and animal and plant health and leading the work to protect plant health, reduce dependency on pesticides and support low-risk and non-chemical alternatives. During the COVID-19 crisis, she has been leading the Commissions work to coordinate the EU’s health response and support Member States to tackle the outbreak.
Nele Leosk is an Ambassador-at-Large for Digital Affairs at the Ministry of Foreign Affairs, Estonia. She is devoted to digital transformation of governments, economies and societies at large. Previously, she acted as the Executive Director of IGL, a research and consulting company specializing in digital governance. She also served as the Programme Director at e-Governance Academy in Estonia, and at the Foresight Centre of the Parliament of Estonia, looking at how technological trends could adhere public governance and digital economy. She has experienced the life of international and inter-governmental organisations such as the UNDP, UNU-eGOV, and OECD as well as academia. She holds a PhD in Political and Social Sciences from the European University Institute (EUI), Italy, and she is a former Fulbright-Schuman grantee at the National Centre for Digital Government at the University of Massachusetts Amherst and at the Governance Lab at New York University, USA.
Marin has been actively engaged in politics since 2006. In 2015, Marin was elected to Parliament for her first run. There she has been member of the Grand Committee, Legal Affairs Committee and Environment Committee. She is member of Tampere city council, which she chaired in 2013–2017. In 2014, Marin was elected as a second deputy party leader of the Social Democratic Party, and since 2017 she has served as the First Deputy Party Leader. In August 2020, Marin was elected as Chair of the Social Democratic Party. During the government formation talks in spring 2019, Marin chaired the negotiating table that addressed the theme ‘Carbon neutral Finland that protects biodiversity’. She served as Minister of Transport and Communications in the Rinne Government. Sanna Marin was appointed Prime Minister on 10 December 2019. Marin is the third female Prime Minister of Finland and the youngest prime minister in Finland’s history.
Mariana Mazzucato (PhD) is Professor in the Economics of Innovation and Public Value at University College London (UCL), where she is Founding Director of the UCL Institute for Innovation & Public Purpose (IIPP). She received her BA from Tufts University and her MA and PhD from the Graduate Faculty of the New School for Social Research. She advises policy makers around the world on innovation-led inclusive and sustainable growth. Her current roles include being Chair of the World Health Organization's Council on the Economics of Health for All and a member of the Scottish Government’s Council of Economic Advisors, the South African President’s Economic Advisory Council, the OECD Secretary General’s Advisory Group on a New Growth Narrative, the UN High Level Advisory Board for Economic and Social Affairs, Argentina’s Economic and Social Council, Vinnova’s Advisory Panel in Sweden, and Norway’s Research Council. Previously, through her role as Special Advisor for the EC Commissioner for Research, Science and Innovation (2017-2019), she authored the high-impact report on Mission-Oriented Research & Innovation in the European Union, turning “missions” into a crucial new instrument in the European Commission’s Horizon innovation program.
John G. Meara, MD, DMD, MBA is the Kletjian Professor of Global Surgery, Director of the Program in Global Surgery and Social Change, and Professor of Surgery in the Department of Surgery at Harvard Medical School. Dr. Meara serves as the Plastic Surgeon-in-Chief of the Department of Plastic & Oral Surgery at Boston Children's Hospital. He was Co-Chair for the Lancet Commission on Global Surgery and was a commissioner on the Lancet Global Health Commission on High Quality Health Systems in the SDG Era and the Lancet Oncology Commission. In 2008 he created the Paul Farmer Global Surgery Fellowship program. He is also interested in value-based health care and implementation science research, including time driven activity-based cost research and outcomes research. Dr. Meara has led several ICHOM projects focusing on outcomes reporting and international benchmarking.
The son of a former European Commissioner, lawyer Charles Michel became Belgium's youngest prime minister since 1845 when he was elected at the age of 38 in 2014. Michel leads the Francophone-liberal Mouvement Reformateur (MR), which represented only 25% of the French-speaking population when he entered a coalition five years ago with, among others, the right-wing nationalist Flemish NVA party. As a liberal, Michel is part of the group in the European Parliament to which France's ruling REM group of President Emmanuel Macron belongs. Michel was one of the first EU politicians to suggest the bloc was heading towards a 'two-tier' union because of migration, as some member states reluctant to take in migrants could lose some of their EU rights. He fell out with the NVA over his refugee policy in December and new elections were called in May. They were inconclusive, and Michel remained in post as interim premier while a new government coalition tried to organize itself. Michel qualified as a lawyer in Brussels and is fluent in Dutch, English and French.
Bernd Montag, Ph.D., has been CEO of Siemens Healthineers since February 2015. As of March 2018, the company is listed on the Frankfurt Stock Exchange as Siemens Healthineers AG (SHL). In the same year, Siemens Healthineers entered the technology index TecDAX and the mid-cap index MDAX. Bernd Montag joined Siemens in 1995. He held positions in corporate quality management and sales in the hearing aid business before moving to the imaging systems unit in 1999, where he served as a product manager for computed tomography and as the head of marketing for the magnetic resonance business. In 2004, he assumed overall responsibility for computed tomography, and in 2008, he was named President of the imaging and therapy division, which combined the overall business of diagnostic imaging and image-guided therapies. Bernd Montag completed his studies in Physics at the Friedrich-Alexander-University, Erlangen-Nuremberg, and earned a Ph.D. in theoretical multi-particle physics.
Dr. Moore leads Microsoft’s Health efforts globally and is responsible for product strategy, product development, and research including AI and machine learning technology for healthcare and life sciences. He is also Microsoft’s senior executive leading dedicated research and development collaborations with Microsoft’s strategic alliance partners in this domain with the goal of enabling a more open, interoperable, and AI-infused foundation for healthcare delivery that aspires to enable access to healthcare for all globally. Dr. Moore is an engineer (MIT PhD), practicing neuroradiologist, clinical informaticist, neuroscientist, and innovator experienced in assembling and inspiring highly talented teams to positively transform healthcare for the benefit of humankind.
Dr. John Nkengasong is Director of the African Centres for Disease Control and Prevention. Until recently he was the Associate Director for Laboratory Science and Chief of the International Laboratory Branch at the Division of HIV & TB, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Atlanta. In addition, Dr. Nkengasong co-chairs the US President’s Emergency Plan for AIDS Relief’s (PEPFAR) Laboratory Technical Working Group and serves as the founding chair of Board of Directors for the African Society for Laboratory Medicine.
Dr Anders Nordström is the Swedish Ambassador for Global Health at the Ministry for Foreign Affairs in Stockholm. As a medical doctor from the Karolinska Institute, Sweden, Dr Nordström has a background that combines development experience with national and international health policy and planning, and global strategic leadership. His first international assignments were with the Swedish Red Cross in Cambodia and the International Committee of the Red Cross in Iran. He worked for the Swedish International Development Cooperation Agency (Sida) for 12 years, including three years as Regional Advisor in Zambia and four years as Head of the Health Division in Stockholm. He served as Acting Director-General of WHO from 23 May 2006 until 3 January 2007 following the sudden death of Dr LEE Jong-Wook, Director-General. After the successful handing over to Dr Margaret Chan, Dr Nordström was appointed Assistant Director-General for Health Systems and Services, which focuses on scaling up health services, human resources for health, health financing, health information systems, pharmaceuticals and health technologies. Dr Nordström was appointed Ambassador for HIV/AIDS at the Swedish Ministry for Foreign Affairs by the Government and in 2012 as the world’s first Ambassador for Global Health. He has served as board member of the Global Fund to fight AIDS, TB and Malaria, GAVI, UNAIDS and PMNCH and was a member of several international task forces, committees and working groups.
Stefan Oelrich is a member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division, a position he has held since November 2018. Prior to joining the company, he was on the Executive Committee of Sanofi, leading its global Diabetes & Cardiovascular business. During his seven-year tenure, he was also at the helm of Sanofi Germany, Switzerland and Austria, as well as the Diabetes and Cardiovascular business unit in Europe. From 1989 to 2011, Mr. Oelrich held various leadership positions in the health care business of Bayer AG with extensive international experience spanning Latin America (Argentina, Uruguay), Europe (France, Belgium) and the United States. Mr. Oelrich is a member of the Supervisory Board of the university hospital Charité, member of the Supervisory Board of the Berlin Institute of Health and member of the Board of the American Chamber of Commerce in Germany.
Dr. Bernd Ohnesorge, PhD, is President of Europe, Middle East and Africa (EMEA) of Siemens Healthineers. Previously, he had served for four years as head of the Magnetic Resonance Business Unit. Dedicated to the advancement of medical technologies, he previously held several leading positions at Siemens including the position of the head of the X-Ray Imaging Products Business Unit in 2010 and 2011 as well as the leadership position of Siemens Healthcare in China and North-East Asia from 2006 to 2010.
He joined Siemens after the completion of his master’s degree in data communication and digital signal processing at the University of Erlangen in 1994. While serving in several R&D and management positions within the Computed Tomography Business Unit between 1994 and 2006, he finished his PhD thesis on methods for cardiac CT imaging in June 2002 at the Institute of Clinical Radiology of the Ludwig-Maximilian-University in Munich, Germany.
Dr Ngozi Okonjo-Iweala is a global finance expert, an economist and international development professional with over 30 years of experience working in Asia, Africa, Europe, Latin America and North America. Dr Okonjo-Iweala was formerly Chair of the Board of Gavi, the Vaccine Alliance. She was recently appointed as African Union (AU) Special Envoy to mobilise international financial support for the fight against COVID-19 and WHO Special Envoy for Access to COVID-19 Tools Accelerator. Previously, Dr. Okonjo-Iweala twice served as Nigeria's Finance Minister (2003-2006 and 2011-2015) and briefly acted as Foreign Minister in 2006, the first woman to hold both positions. She had a 25-year career at the World Bank as a development economist. As a development economist and Finance Minister, Dr Okonjo-Iweala steered her country through various reforms ranging from macroeconomic to trade, financial and real sector issues. She is renowned as the first female and African candidate to contest for the presidency of the World Bank Group in 2012.
Tolullah Oni is a Public Health Physician Scientist and urban epidemiologist, a Clinical Senior Research Associate and joint lead of the Global Public Health at the University of Cambridge MRC Epidemiology Unit, and Honorary Associate Professor in Public Health at the University of Cape Town. Born in Lagos, she completed her medical training at University College London, postgraduate medical training in the UK and Australia, a Masters degree in Public Health (Epidemiology) at the University of Cape Town, and a research doctorate in Clinical Epidemiology at Imperial College London. She leads the Research Initiative for Cities Health and Equity (RICHE) conducting transdisciplinary urban health research generating evidence to support development and implementation of healthy public policies in rapidly growing cities, with a focus on Africa. She serves on several advisory boards including Future Earth and the African Academy of Science Open Research Platform; and is an editorial board member of Lancet Planetary Health, Cities and Health, and the Journal of Urban Health. Profiled in the Lancet (2016), Science magazine (2018), and the British Medical Journal (2019), she is a Fellow of the African Academy of Sciences, past co-chair of the Global Young Academy, 2015 Next Einstein Forum Fellow, and a 2019 World Economic Forum Young Global Leader.
Mari Pangestu is the World Bank Managing Director of Development Policy and Partnerships since March 1, 2020. She provides leadership and oversees the research and data group of the World Bank (DEC), the work program of the World Bank’s Global Practice Groups, and the External and Corporate Relations function. Ms. Pangestu has served as Indonesia’s Minister of Trade from 2004-2011 and as Minister of Tourism and Creative Economy from 2011-2014. She has had vast experience of over 30 years in academia, second track processes, international organizations and government working in areas related to international trade, investment and development in multilateral, regional and national settings. Most recently, Ms. Pangestu was a Senior Fellow at the Columbia School of International and Public Affairs, as well as Professor of International Economics at the University of Indonesia, adjunct professor at the Lee Kuan Yew School of Public Policy and Crawford School of Public Policy, Australian National University and a Board Member of Indonesia Bureau of Economic Research (IBER), as well as Centre for Strategic and International Studies (CSIS), Jakarta. Ms. Pangestu served as Chairperson of the Board of Trustees of the International Food Policy Research Institute (IFPRI) in Washington D.C and as advisor to the Global Commission on the Geopolitics of Energy Transformation of International Renewable Energy Agency (IRENA) in Abu Dhabi. Her record of board and task force service includes the Leadership Council of the UN Sustainable Development Solutions Network (SDSN), co-chair of the expert group for the High-Level Panel for a Sustainable Ocean Economy, the panel of the WHO health initiative, the Equal Access Initiative, commissioner for the Low Carbon Development Initiative of Indonesia and executive board member of the International Chamber of Commerce (ICC). She has also served on the board of several private sector companies.
Vikram Patel is a professor of global health and social medicine and psychiatrist whose work over the past two decades has focused on reducing the treatment gap for mental disorders in low resource countries. He is Pershing Professor of Global Health and Social Medicine at the Department of Global Health and Social Medicine of Harvard Medical School in Boston and was awarded a Wellcome Trust Principal Research Fellowship in 2015. He is the Co-Founder and former Director of the Centre for Global Mental Health at the London School of Hygiene and Tropical Medicine (LSHTM), Co-Director of the Centre for Control of Chronic Conditions at the Public Health Foundation of India, and the Co-Founder of Sangath, an Indian NGO dedicated to research in the areas of child development, adolescent health, and mental health. In April 2015, he was listed as one of the world's 100 most influential people by TIME magazine.
Axel R. Pries is a Professor of Physiology and Dean of the Charité - Universitätsmedizin Berlin. His major research fields are microcirculation, organ perfusion, endothelial function, endothelial surface, vascular adaptation, angiogenesis, tumor microcirculation and blood rheology.
Gabriela Ramos is the Assistant Director-General for the Social and Human Sciences of UNESCO, where she oversees the contributions of the institution to build inclusive and peaceful societies. Her agenda includes the achievement of social inclusion and gender equality, advancing youth development; promotion of values through sports; anti-racism and antidiscriminatory agenda and ethics of artificial inteligence. Prior to this position, Ms. Ramos served as the Chief of Staff and Sherpa to the G20/G7/APEC in the OECD, contributing to the global agenda as well as leading the OECD's New Approaches to Economic Challenges, Inclusive Growth Initiative, Gender Strategy and the work on well-being and children. Her work to promote gender equality earned her the 2017 and 2018 Forbes Excellence award as well as being included as part of Apolitical’s 100 Most Influential People in Gender Policy in both 2018 and 2019.
A former Chief Executive Officer of Standard Chartered PLC, Sands has been a research fellow at Harvard University since 2015, working on a range of research projects in financial markets and regulation, fintech, and global health. His engagement with global health issues includes chairing the US National Academy of Medicine's Commission on a Global Health Risk Framework for the Future, chairing the World Bank's International Working Group on financing preparedness, authoring several papers on infectious disease crises, providing policy direction to the UK's National Health Service, and being an active member on both the US National Academy of Science's Committee on Ensuring Access to Affordable Drugs and the Forum on Microbial Threats. Sands has served on various boards and commissions, including as Lead Non-Executive Director of the Department of Health in the United Kingdom, and as a Director of the World Economic Forum.
Stéphanie Seydoux has been appointed French Ambassador for Global health in May 2018. She has served as the head of the Women’s Rights and Gender Equality Division, assistant to the Director General of Women’s Affairs and social cohesion from 2014 to 2017. Since November 2017, she was in charge of a support mission to the government for the revision of the bioethics law. After starting her career at the Ministry of Foreign Affairs, Stéphanie Seydoux joined the General Inspectorate of Social Affairs (IGAS) in 2004. From 2007 to 2010, she was head of the department for the promotion of equality at the High commission against discrimination and for equality (HALDE). From 2010 to 2013, she joined the Ministry of Foreign Affairs as first counsellor, deputy head of post at the French Embassy in Kenya.
Dr Princess Nothemba (Nono) Simelela, from South Africa, was most recently WHO's Assistant Director-General for Family, Women, Children and Adolescents. She has more than 30 years of experience as an obstetrician, academic, advocate and government official, and has previously served as Special Advisor to the Vice President of the Republic of South Africa on Social Policy, where she supported the multisectoral, government wide response for HIV. Other previous senior leadership roles held by Dr Simelela include serving as the Chief Executive Officer of the South African National AIDS Council, and as the Director of Technical Knowledge and Support for the International Planned Parenthood Federation. Dr Simelela has presented and published widely on women’s health and contributed to the development of key guidelines on the prevention of mother-to-child transmission of HIV.
Dr. Henry Skinner joined the Fund from Tekla Capital Management, where he was Senior Vice President, Venture. Prior to joining Tekla, Dr. Skinner Served as Deputy Head and Managing Director of Novartis Venture Fund. In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics. Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.
Dennis J. Snower is President of the Global Solutions Initiative, which provides policy advice to the G20. He is Senior Research Fellow of the Blavatnik School of Governance, Oxford University; non-resident fellow of The Brookings Institution and visiting Professor at University College, London. Starting in September 2019, he will be Senior Professor at the Hertie School of Governance, Berlin. Furthermore, he is a Research Fellow at the Center for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich). Dennis J. Snower was born in Vienna, Austria, where he went to the American International School. He earned a BA and MA from New College, Oxford University, and an MA and a PhD at Princeton University. He served most recently as President of the Kiel Institute for the World Economy, where he is now a president emeritus, and was previously Professor of Economics at Birkbeck College, University of London.
Jens Spahn is Germany’s Federal Minister of Health. He is a member of the German Bundestag and part of the center-right party Christian Democratic Union of Germany (CDU), which governs in partnership with the center-left Social Democratic Party of Germany (SPD). Spahn was party speaker for health policy from 2009-2015 and then served as Parliamentary State Secretary to the Federal Minister of Finance before becoming Minister of Health in March 2018.
Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world. Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.
Dr. Nathalie Strub-Wourgaft joined DNDi as Clinical Development Director in February 2009 and is now the Director of Neglected Tropical Diseases. Dr Strub-Wourgaft, who most recently served as Director, Clinical Development at Trophos, has over 15 years of clinical development experience, including with Pfizer from 2000 to 2003, and Lundbeck from 1995 to 1999. She also served as Medical Director for a CRO from 2004 to 2005 as well as for the French office of Aspreva from 2005 to 2008. Dr Strub-Wourgaft graduated as Medical Doctor from Necker Hospital, Université René Descartes in Paris in 1983.
Charlene Sunkel is a global voice for the rights of people with lived experience of mental health conditions. She has been working in the field of mental health, advocacy and human rights since 2003. She authored several papers from a lived experience perspective published in well renowned international medical journals. She has written and produced theatre plays and a short feature film on mental disorders. Charlene Sunkel had been involved in the review and drafting of various policies and legislation in South Africa and provided technical assistance to international mental health related reports and documents. She serves on a number of national and international boards and committees. Charlene Sunkel is the Principal Coordinator for the Movement for Global Mental Health. She is the Founder/ CEO of the Global Mental Health Peer Network which was officially launched at the 5th Global Mental Health Summit in 2018. She is also a faculty member of the Indian Law College as guest lecturer for the International Diploma in Mental Health, Human Rights and Law. Charlene Sunkel was diagnosed with schizophrenia in 1991 which led to her passion for mental health advocacy and human rights, where she received a number of national and international awards for her work, with the latest award for Outstanding Achievement in Mental Health from the Swiss Foundation and the World Health Organisation.
Dr. Soumya Swaminathan was most recently WHO's Deputy Director-General for Programmes. A paediatrician from India and a globally recognized researcher on tuberculosis and HIV, she brings with her 30 years of experience in clinical care and research and has worked throughout her career to translate research into impactful programmes. Dr Swaminathan was Secretary to the Government of India for Health Research and Director General of the Indian Council of Medical Research from 2015 to 2017. In that position, she focused on bringing science and evidence into health policy making, building research capacity in Indian medical schools and forging south-south partnerships in health sciences. From 2009 to 2011, she also served as Coordinator of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases in Geneva. She received her academic training in India, the United Kingdom of Great Britain and Northern Ireland, and the United States of America, and has published more than 350 peer-reviewed publications and book chapters. She is an elected Foreign Fellow of the US National Academy of Medicine and a Fellow of all three science academies in India. She has previously been on several WHO and global advisory bodies and committees.
Mr. Sy was Secretary General of the International Federation of Red Cross and Red Crescent Societies (IFRC) from 2014 to 2019. He currently serves as Chair of the Board of the Kofi Annan Foundation and Co-Chair of the Global Preparedness Monitoring Board. Prior to his leadership role at the IFRC, Mr. Sy was UNICEF’s Director of Partnerships and Resource Development in New York. He has also served as UNICEF Regional Director for Eastern and Southern Africa and Global Emergency Coordinator for the Horn of Africa. Mr. Sy held leadership positions with the United Nations Development Programme in New York, with the Global Fund to fight AIDS, Tuberculosis and Malaria and with UNAIDS. Before joining the United Nations, Mr. Sy served as Director of Health and Development Programmes with Environment and Development Action in the Third World in Dakar, Senegal.
Lia Tadesse Gebremedhin is an Ethiopian politician who is serving as Minister of Health since March 2020. Prior to this appointment, Lia served as State Minister of Health from November 2018. Before that, she was Program Director at the University of Michigan's Center for International Reproductive Health Training, CEO and Vice Provost in St. Paul's Hospital Millennium Medical College in Addis Ababa and Project Director of USAID's Maternal and Child Survival Program at Jhpiego-Ethiopia. Lia Tadesse Gebremedhin has served in the Health Sector for over 20 years.
Özlem Türeci, M.D., Co-Founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience. Türeci has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf vaccine candidates and other types of immunotherapies which are currently in clinical development. Türeci leads the clinical development of BioNTech’s “Project Lightspeed,” the company’s successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year. Türeci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. The company was acquired by Astellas in 2016. She currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recent recipient of the German Sustainability Award, among other notable recognitions. Türeci is married to Prof. Ugur Sahin.
Aylin Tüzel is the Country Manager of Pfizer Germany. After joining Pfizer Turkey in 1992, she worked in sales and marketing and was responsible for various indications and products – among others as Marketing Director, Business Unit Lead for Primary Care and Business Unit Lead Specialty Care. She gained international experience as Cluster Lead of the Vaccines Business Unit for Turkey, Kazakhstan, Israel and the Southeast Region. In 2018, Aylin Tüzel moved to Berlin with her family and was responsible for the Vaccines Business Unit in Germany. In May 2021, she was named Country Manager of Pfizer Germany. Aylin graduated from the Faculty of Business Administration at the University of Istanbul. She is married with two children.
Juan Pablo Uribe, MD, is the Global Director for Health Nutrition and Population at the World Bank and Director of the Global Financing Facility for Women Children and Adolescents (GFF). Previously, Mr. Uribe was the CEO of Healthcare Providers for United Healthcare/Banmédica for Chile and Peru and served from 2018 to 2019 as Minister of Health and Social Protection of Colombia. Prior to that, he was the Director General of the Fundación Santa Fe de Bogotá, a leading organization in Colombia working in health care, health education and public health. Between 2009 and 2011, he was the World Bank´s Health Sector Manager for East Asia and the Pacific. In his career, first as a medical doctor specializing in public health and public administration, and later in both public and private sector organizations, Mr. Uribe has contributed significantly to the development of public health, health systems and public policies.
Olivier Véran holds an executive Master in Health Management and Policy at Sciences-Po Paris and was the Vice President and spokesperson of the Inter Syndicat National des Internes des Hôpitaux (ISNIH). He has worked as a neurologist, was the Assistant Clinical Head in Vascular Neurology Intensive Care Unit (stroke management), a lecturer at the Grenoble Faculty of Medicine and he runs a neurology day hospital. He was Member of Parliament for the first constituency of Isère from July 22, 2012 to April 5, 2015, and has been Member of Parliament again since June 2017. He assumed the role of Minister of Solidarity and Health in 2020.
Ursula von der Leyen is a German politician and has been the first female President of the European Commission since December 2019. She is a member of the Christian Democratic Union (CDU) and the European People's Party (EPP). She has previously served in the federal government of Germany as Federal Minister of Defence, Federal Minister of Labor and Social Affairs as well as Federal Minister for Family Affairs, Senior Citizens, Women and Youth.
Prof. Lothar H. Wieler is president of the Robert Koch Institute, the national public health institute in Germany. The Robert Koch Institute is in charge of health monitoring and surveillance, pandemic preparedness, and preventing and recognizing attacks with biological agents. Prof. Wieler's own research focus has been zoonoses, particularly on molecular mechanisms, enabling bacterial pathogens to infect different hosts, and develop antibiotic resistance. He is author/co-author of more than 220 peer-reviewed papers. Wieler is also deputy spokesperson of the intersectoral research consortium InfectControl 2020 and a member of the scientific advisory board of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), the WHO Europe Advisory Committee on Health Research (EACHR), and the WHO Strategic and Technical Advisory Group on Infectious Hazards (STEG-IH). Since 2010, he is an elected member of the German National Academy of Sciences.
Christoph Zindel, M.D., has been a Member of the Managing Board of Siemens Healthineers since October 2019. Christoph Zindel joined the healthcare business of Siemens in 1998 as Segment Manager and served in diverse management positions with increasing responsibility within the magnetic resonance business unit. From 2012 on he served as Chief Executive Officer of PETNET Solutions based in Knoxville, TN, United States, before joining Beckman Coulter to head the hematology and urinanalysis business as Senior Vice President, based in Miami, FL, United States. After he returned to Siemens Healthineers in 2015, he served as Senior Vice President and general manager of the magnetic resonance business line and became President of the diagnostic imaging business in 2018. Christoph Zindel holds a Doctor of Medicine M.D. (Dr.) from the J.W. Goethe University Frankfurt, Germany.